Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triheptanoin in Heart Failure
NCT01787851Phase 2Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Feb 2013
- Primary completion
- Feb 2014
- Modality
- SLNs, Nanostructured Lipid Carriers, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of triheptanoin in dilated cardiomyopathy (DCM) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Cardiac Index at 6 hours. Planned start Feb 2013; status: withdrawn.
02
Drugs
triheptanoin
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NCT01787851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787851.